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Dysregulated signals from the external environment and/or the internal milieu of the skin can lead to
pathological conditions such as psoriasis. Di Meglio et al. (2014) show that the environment-responsive tran-
scription factor AhR acts in keratinocytes to suppress psoriatic lesions.Psoriasis is a chronic, immune-mediated
disease characterized by itchy, red, scaly
patches on the skin; these patches
can bleed and be painful. Psoriasis can
also be associated with an inflammatory
arthritis, which can be debilitating. Skin
pathology is associated with excessive
secretion of inflammatory cytokines,
such as IL-23, IL-17, and IL-22, as well
as with infiltration of neutrophils and
T cells (Lowes et al., 2013). Susceptibility
to psoriasis has a genetic basis, andmany
gene polymorphisms have been impli-
cated (Roberson and Bowcock, 2010).
However, whether and to what extent
environmental stimuli contribute to the
disease remains unclear. In this issue of
Immunity, Di Meglio et al. show that pso-
riasis depends on abnormal interactions
between the environment, skin keratino-
cytes, and the immune system. The aryl
hydrocarbon receptor (AhR) in keratino-
cytes is at the crossroads of these inter-
actions (Di Meglio, 2014).
AhR is a ligand-activated transcription
factor that was originally characterized
for its function in the metabolism of envi-
ronmental pollutants, such as dioxin and
other polycyclic aromatic hydrocarbons
(PAHs) (Nguyen and Bradfield, 2008).
Upon ligand binding, AhR translocates
from the cytosol to the nucleus, forms a
dimer with the AhR nuclear translocator,
binds to specific DNA sequences known
as dioxin responsive elements, and
thus induces the transcription of enzymes
belonging to the cytochrome P450
superfamily of monooxygenases. These
enzymes catalyze the oxidation of PAHs,
facilitating their excretion through bile
and urine. AhR detects not only pollutants
but also many other environmental com-
pounds, such as indoles and flavonoids
of dietary origin as well as tryptophan me-
tabolites that are generated by exposure
to UV light or by bacteria of the intestinalmicroflora (Fritsche et al., 2007; Nguyen
and Bradfield, 2008; Zelante et al.,
2013). Additionally, AhR can sense kynur-
enine and other endogenous tryptophan
metabolites, which are generated by two
enzymes, indoleamine 2,3-dioxygenase
and tryptophan 2,3-dioxygenase (Fallar-
ino et al., 2012).
AhR has been extensively studied
by toxicologists (Nguyen and Bradfield,
2008) but only more recently captured
the attention of immunologists after it
was found in various cells of the immune
system and was shown to control the dif-
ferentiation and/or function of dendritic
cells (DCs), Th17 and Treg cells, and
innate lymphoid cells (ILCs) (Nguyen
et al., 2013; Quintana and Sherr, 2013).
Because of its sensitivity to environmental
stimuli, AhR has been most extensively
studied in the context of immune re-
sponses at the gastrointestinal barrier,
which is exposed to AhR ligands
derived from themicrobiota and nutrients.
Because the skin is another important bar-
rier surface colonized by its own unique
microbiota and because the inflammatory
cytokines implicated in psoriasis are ex-
pressed by cell types regulated by AhR,
Di Meglio et al. turned their attention to
the impact of AhR on genes expressed in
psoriatic and nonpsoriatic skin samples.
They defined a psoriatic gene profile
and found that expression of a subset
of psoriasis-related genes, such as inter-
feron-induced genes, decreased in the
presence of an AhR agonist but were
induced by an AhR antagonist.
The potential mitigating activity of the
AhR ligands on psoriasis prompted the
in-depth investigation of a mouse model
of psoriasis, which the authors obtained
by applying the proinflammatory drug imi-
quimod to mouse skin. Mice lacking AhR
were more prone to psoriasis than wild-
type mice; their skin contained more neu-Immunitytrophils and inflammatory cytokines and
chemoattractants. In contrast, treatment
of wild-type mice with an AhR agonist
ameliorated imiquimod-induced psoria-
sis. Given previous evidence of the impact
of AhR on immune responses, one would
expect that a lack of AhR would enhance
DC or T cell responses to imiquimod.
However, in a series of elegant studies
involving conditional AhR-deficient mice
and bone marrow chimeras, Di Meglio
et al. reconstituted AhR-deficient or -suffi-
cient mice with AhR-sufficient hemato-
poietic cells and found that psoriasis
appeared when AhR was missing in
stromal cells rather than T cells, DCs, or
hematopoietic cells in general. Thus,
AhR acts primarily in stromal cells. More-
over, mice with combined deficiency of
AhR and Rag1 recombinase showed
limited psoriatic lesions similar to those
of mice with Rag1 deficiency alone, sug-
gesting that psoriasis depends on the
crosstalk between stromal cells express-
ing AhR and the adaptive immune system.
Di Meglio et al. then turned to in vitro
experiments with primary mouse kerati-
nocytes as well as human keratinocyte
cell lines and found that deficiency or
silencing of AhR made these cells hyper-
responsive to inflammatory cytokines,
particularly IL-1b, which is produced
very early and abundantly in the skin dur-
ing challenge with imiquimod. As a re-
sult, AhR-deficient keratinocytes released
more inflammatory mediators. How does
AhR control keratinocyte response to IL-
1b? Gene expression analysis of skin
samples from AhR-sufficient and -defi-
cient mice treated with imiquimod or
with an AhR agonist showed that AhR
controls transcription factors of the AP-1
family, particularly JunB, which has been
previously implicated in psoriasis and ker-
atinocyte proliferation and differentiation
(Zenz et al., 2005). Consistent with a role40, June 19, 2014 ª2014 Elsevier Inc. 863
Figure 1. AhR Regulation of Keratinocytes
At the epidermal surface, UV light and/or resident microorganisms produce tryptophan and idole break-
down products, including FICZ. These polyaromatic hydrocarbons are ligands for the transcription factor
AhR in keratinocytes, and their binding causes translocation to the nucleus and subsequent transcriptional
changes. In this way, AhR helps reduce keratinocyte responses to cytokines such as IL-1b, leading to
decreased transcription of the AP-1 family member Jun-B, a transcription factor previously implicated
in psoriasis and keratinocyte proliferation. This ultimately results in decreased psoriatic pathology in
AhR-competent compared to AhR-deficient skin. Abbreviations are as follows: T = T cell; ILC = innate
lymphoid cell.
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cient keratinocytes showed enhanced
expression of JunB in response to IL-1b,
whereas a JunB antagonist reduced the
expression of proinflammatory genes in
AhR-deficient keratinocytes.
Overall, this study unveils the
complexity of the interactions underlying
inflammation in psoriasis and most
likely other inflammatory skin conditions.
At the border between the environment
and the organism, keratinocytes of the
skin are constantly exposed to multiple
external and internal stimuli. Environ-
mental factors that engage keratinocyte
AhR lower their sensitivity to inflammatory
stimuli (Figure 1). Pathogenic agents that
cross the keratinocyte barrier stimulate
the immune system to release cyto-
kines that augment keratinocytes’ ability
to attract and activate immune cells. The
type of stimuli that engage keratinocyte
AhR remain to be explored. Di Meglio
et al. used 6-formylindolo[3,2-b]carbazole
(FICZ), a tryptophan metabolite, which
could be induced in keratinocytes by864 Immunity 40, June 19, 2014 ª2014 Elsevexposure to ultraviolet (UV) and visible
light (Fritsche et al., 2007). It is likely that
the skin microbiota also produces tryp-
tophan or indole derivatives that engage
AhR and modulate skin immune re-
sponses through this pathway (Figure 1).
Thus, it will be important to see the impact
of skin microbiota on immune responses
in AhR-deficient mice and, vice versa,
the impact of AhR deficiency on skin
microbiota. Another important point
that deserves further investigation is the
role of AP-1 transcription factors in skin
inflammation. Although JunB promotes
inflammation in the imiquimod psoriasis
model used by Di Meglio et al., in another
study the inducible abrogation of JunB
in keratinocytes triggered chemokine
and cytokine expression, as well as
neutrophil and macrophage recruitment
to the epidermis (Zenz et al., 2005).
Because JunB is part of a dynamic
network of AP-1 transcription factors, it
is possible that the duration of changes
in JunB expression and the mutual bal-
ance with compensatory and/or redun-ier Inc.dant mechanisms affect the impact these
changes have on keratinocytes.
Current therapeutic efforts in psoriasis
focus on the blockade of the IL-23-
IL-17-IL-22 axis (Lowes et al., 2013). Di
Meglio et al. show that blockade of IL-17
in AhR-deficient mice is not sufficient
to block imiquimod-induced skin lesions.
Although the imiquimod-induced model
of psoriasis might not entirely recapitulate
human psoriasis, this result suggests
that there might be additional avenues
for therapeutic intervention in psoriasis,
and generally in other inflammatory skin
conditions, that could exploit the modula-
tory function of AhR. Of note, one of the
oldest treatments for psoriasis has been
the topical application of coal tar, which
consists of complex mixtures of PAHs
and other compounds. Another common
treatment for psoriasis is exposure to UV
light. The ability of PAHs and UV-induced
tryptophan metabolites to activate AhR
might in part explain the efficacy of these
tried-and-true therapies for psoriasis.
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